Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1)
-
Published:2020-11-29
Issue:2
Volume:26
Page:233-283
-
ISSN:1341-9625
-
Container-title:International Journal of Clinical Oncology
-
language:en
-
Short-container-title:Int J Clin Oncol
Author:
Naito Yoichi, , Aburatani Hiroyuki, Amano Toraji, Baba Eishi, Furukawa Toru, Hayashida Tetsu, Hiyama Eiso, Ikeda Sadakatsu, Kanai Masashi, Kato Motohiro, Kinoshita Ichiro, Kiyota Naomi, Kohno Takashi, Kohsaka Shinji, Komine Keigo, Matsumura Itaru, Miura Yuji, Nakamura Yoshiaki, Natsume Atsushi, Nishio Kazuto, Oda Katsutoshi, Oda Naoyuki, Okita Natsuko, Oseto Kumiko, Sunami Kuniko, Takahashi Hideaki, Takeda Masayuki, Tashiro Shimon, Toyooka Shinichi, Ueno Hideki, Yachida Shinichi, Yoshino Takayuki, Tsuchihara KatsuyaORCID, ,
Abstract
Abstract
Background
To promote precision oncology in clinical practice, the Japanese Society of Medical Oncology, the Japanese Society of Clinical Oncology, and the Japanese Cancer Association, jointly published “Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment” in 2017. Since new information on cancer genomic medicine has emerged since the 1st edition of the guidance was released, including reimbursement for NGS-based multiplex gene panel tests in 2019, the guidance revision was made.
Methods
A working group was organized with 33 researchers from cancer genomic medicine designated core hospitals and other academic institutions. For an impartial evaluation of the draft version, eight committee members from each society conducted an external evaluation. Public comments were also made on the draft. The finalized Japanese version was published on the websites of the three societies in March 2020.
Results
The revised edition consists of two parts: an explanation of the cancer genomic profiling test (General Discussion) and clinical questions (CQs) that are of concern in clinical practice. Particularly, patient selection should be based on the expectation that the patient's post-test general condition and organ function will be able to tolerate drug therapy, and the optimal timing of test should be considered in consideration of subsequent treatment plans, not limited to treatment lines.
Conclusion
We expect that the revised version will be used by healthcare professionals and will also need to be continually reviewed in line with future developments in cancer genome medicine.
Funder
Ministry of Health, Labour and Welfare
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology,General Medicine,Surgery
Cited by
49 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|